Company

Imugene Limited

Headquarters: Sydney, NSW, Australia

CEO: Ms. Leslie Chong

ASX: IMU -7.50%

Market Cap

A$396.5 Million

AUD as of July 1, 2024

US$264.1 Million

Market Cap History

Imugene Limited market capitalization over time

Evolution of Imugene Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Imugene Limited

Detailed Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Imugene Limited has the following listings and related stock indices.


Stock: ASX: IMU wb_incandescent

Details

Headquarters:

37 Bligh Street

Suite 1006 Level 10

Sydney, NSW 2000

Australia

Phone: 61 3 9824 5254